New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
The Latest on: Cancer Immunotherapy
via Google News
The Latest on: Cancer Immunotherapy
- Triad Teen, Family Hopes Immunotherapy Keeps Cancer Away on February 9, 2019 at 9:08 pm
On Saturday, Johnny Kemp and his family flew to Philadelphia to start immunotherapy at the Children's Hospital of Philadelphia. It's a process that uses his own cells to fight off cancer cells. […]
- Immunotherapy effective for cancer patients with HIV on February 7, 2019 at 10:24 am
Feb. 7 (UPI) --Immunotherapy has shown promise in treating cancer in HIV patients, a study says. Checkpoint inhibitors kept the viral loads of 93 percent of cancer patients with HIV suppressed, and wa... […]
- Immunotherapy appears better than chemotherapy for aggressive type of skin cancer on February 7, 2019 at 9:42 am
The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and ... […]
- Study finds HIV+ cancer patients benefit from immunotherapy on February 7, 2019 at 8:05 am
The immunotherapy that has revolutionized treatment of many cancers appears to offer similar benefit to cancer patients living with HIV, say researchers at Georgetown Lombardi Comprehensive Cancer ... […]
- The Parker Institute for Cancer Immunotherapy Expands its Network to Include More Rising Stars in Cancer Immunotherapy on February 6, 2019 at 12:00 pm
SAN FRANCISCO, Feb. 6, 2019 /PRNewswire/ -- The Parker Institute for Cancer Immunotherapy recently welcomed seven talented early career researchers in cancer immunotherapy to its network as part of th... […]
- $4.2B deal: GSK and Merck KGaA to develop cancer immunotherapy on February 6, 2019 at 10:40 am
GlaxoSmithKline is teaming up with Merck KGaA of Germany in a multibillion-deal to jointly develop an experimental immunotherapy treatment for multiple difficult-to-treat cancers. Under the terms of t... […]
- Breast Cancer Fight Gets Aid from Immunotherapy and Diabetes Drug Combo on February 6, 2019 at 7:27 am
Cancer researchers have always understood the power of combination therapies—blending two or more drugs together to fight the heterogeneous nature of tumors has helped push a number of patients into r... […]
- GSK to Co-Develop Merck KGaA’s Cancer Immunotherapy Candidate M7824 in $4.2B Alliance on February 5, 2019 at 10:25 am
GlaxoSmithKline will partner with Merck KGaA, Darmstadt, to co-develop and co-commercialize the cancer immunotherapy candidate M7824 (bintrafusp alfa), through a collaboration that could generate more ... […]
- GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy on February 5, 2019 at 7:51 am
FRANKFURT (Reuters) - GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a ... […]
- Emerging Immunotherapy Approaches For Urothelial Cancer on February 4, 2019 at 3:04 pm
Today we are discussing immunotherapy approaches for the treatment of advanced urothelial cancer with Dr. Petros Grivas, MD, PhD, a medical oncologist who focuses on genitourinary cancers at the Seatt... […]
via Bing News